Plaque psoriasis; This spontaneous case was reported by a consumer and describes the occurrence of PSORIASIS (Plaque psoriasis) in a 73-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for Plaque psoriasis and Psoriatic arthritis.    The patient's past medical history included Plaque psoriasis. Previously administered products included for Plaque psoriasis: Humira.   On 22-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 24-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 30-Oct-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 20-Apr-2022, received fourth dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received dose of ADALIMUMAB (HUMIRA) (Subcutaneous) at an unspecified dose. On an unknown date, the patient experienced PSORIASIS (Plaque psoriasis). At the time of the report, PSORIASIS (Plaque psoriasis) had not resolved.            No concomitant medication information provided. Patient received 1st booster shot on 30 Oct 2021 and 2nd booster shot on 20 Apr 2022.  No treatment medication information provided. Causality for HUMIRA (ADALIMUMAB): The reporter's causality for the event of symptoms of plaque psoriasis was not provided and the reporter's causality for the event of years ago when using Humira it worked well but did not work now/symptoms not bettering with Humira (adalimumab) was a reasonable possibility.  Company Comment: This spontaneous  case concerns a 73 year old male patient with relevant medical history of Psoriasis ( years ago )   taking  ADALIMUMAB (HUMIRA) , a Co-suspect, non-company product  , initially vaccinated with  Covid 19 vaccine using mRNA-1273 vaccine., who experienced Non-serious , unexpected events  of Psoriasis  which occurred on an unknown date after vaccination with the four doses of mRNA-1273 vaccine. ( 2 primary doses and 2 booster doses ) . This patient  experienced symptoms of plaque Psoriasis years ago when using  Humira   previously it worked well  but now noted  did not work , symptoms were not getting any better.  It was noted in the report that this patient was vaccinated for four doses using mRNA-1273 vaccine .  Outcome of the event was reported as unknown. The history of psoriasis , the age of this patient and the Co -Suspect drug ADALIMUMAB ( Humira ) are considered as confounders for the event Psoriasis . The benefit -risk relationship of mRNA -1273 ( Moderna Covid 19 Vaccine) is not affected by this report.; Sender's Comments: This spontaneous  case concerns a 73 year old male patient with relevant medical history of Psoriasis ( years ago )   taking  ADALIMUMAB (HUMIRA) , a Co-suspect, non-company product  , initially vaccinated with  Covid 19 vaccine using mRNA-1273 vaccine., who experienced Non-serious , unexpected events  of Psoriasis  which occurred on an unknown date after vaccination with the four doses of mRNA-1273 vaccine. ( 2 primary doses and 2 booster doses ) . This patient  experienced symptoms of plaque Psoriasis years ago when using  Humira   previously it worked well  but now noted  did not work , symptoms were not getting any better.  It was noted in the report that this patient was vaccinated for four doses using mRNA-1273 vaccine .  Outcome of the event was reported as unknown. The history of psoriasis , the age of this patient and the Co -Suspect drug ADALIMUMAB ( Humira ) are considered as confounders for the event Psoriasis . The benefit -risk relationship of mRNA -1273 ( Moderna Covid 19 Vaccine) is not affected by this report.